The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Making of the Guidelines

Making of the Guidelines

March 18, 2011 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although FRAX has some limitations—for example, it does not consider dose response effects and is relevant only for untreated patients—Dr. Grossman said the tool remains useful for clinicians.

You Might Also Like
  • New GIOP Guidelines Available
  • Glucocorticoids a Fracture Risk at Any Dose
  • Updated Guidelines and New Therapies for Osteoporosis Coming this Year
Explore This Issue
March 2011
Also By This Author
  • Patient-Driven Care

The 2010 recommendations also added newer agents such as zoledronic acid and teriparatide but removed therapies such as estrogen replacement and testosterone, she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The new recommendations from include graphs that make it easy to determine a patient’s risk for fracture based on their FRAX results, race, age, and, for women, whether or not they are premenopausal or postmenopausal (see Figures 1 and 2, p. 44).

Vanessa Caceres is a medical writer in Bradenton, Florida.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res. 2010;62:1515-1526.
  2. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224-3229.
  3. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005;52:2485-2494.
  4. World Health Organization Collaborating Centre for Metabolic Bone Diseases. WHO Fracture Risk Assessment Tool. www.shef.ac.uk/ FRAX. Accessed January 26, 2011.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: 2010 ACR/ARHP Annual Scientific Meeting, bone, Glucocorticoids, Osteoporosis, SteroidIssue: March 2011

You Might Also Like:
  • New GIOP Guidelines Available
  • Glucocorticoids a Fracture Risk at Any Dose
  • Updated Guidelines and New Therapies for Osteoporosis Coming this Year
  • New Treatment Guidelines to Be Presented at the 2016 ACR/ARHP Annual Meeting

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.